Vireo Growth (VREOF) Total Non-Current Liabilities (2021 - 2026)
Vireo Growth's (VREOF) quarterly Total Non-Current Liabilities came in at $604.7 million in Q1 2026, up 166.89% year-on-year from $226.6 million in Q1 2025, and up 19.08% quarter-over-quarter from $507.8 million in Q4 2025.
Vireo Growth (VREOF) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Vireo Growth has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $604.7 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $604.7 million, up 166.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $604.7 million (up 166.89% YoY), and the FY2025 annual result was $507.8 million, up 127.41% from the prior year.
- Total Non-Current Liabilities came in at $604.7 million for Q1 2026 at Vireo Growth, up from $507.8 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $604.7 million in Q1 2026 to a low of $155.7 million in Q4 2022.
- The 5-year median for Total Non-Current Liabilities is $217.0 million (2024), against an average of $287.1 million.
- Across the five-year window, Total Non-Current Liabilities grew 6.23% in 2025 and surged 166.89% in 2026, its largest moves.
- Vireo Growth's Total Non-Current Liabilities stood at $155.7 million in 2022, then advanced by 27.92% to $199.2 million in 2023, then grew by 12.11% to $223.3 million in 2024, then soared by 127.41% to $507.8 million in 2025, then grew by 19.08% to $604.7 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $604.7 million (Q1 2026), $507.8 million (Q4 2025), and $432.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Vireo Growth | - | - | 59.30 Mn | 604.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 604.70 Mn |
| Dec 31, 2025 | 507.80 Mn |
| Sep 30, 2025 | 432.61 Mn |
| Jun 30, 2025 | 389.44 Mn |
| Mar 31, 2025 | 226.57 Mn |
| Dec 31, 2024 | 223.30 Mn |
| Sep 30, 2024 | 204.87 Mn |
| Jun 30, 2024 | 217.04 Mn |
| Mar 31, 2024 | 213.28 Mn |
| Dec 31, 2023 | 199.19 Mn |
| Sep 30, 2023 | 184.29 Mn |
| Jun 30, 2023 | 173.66 Mn |
| Dec 31, 2022 | 155.71 Mn |
| Sep 30, 2021 | 110.17 Mn |
| Jun 30, 2021 | 52.73 Mn |
| Mar 31, 2021 | 58.01 Mn |